BOT 4.23% 34.0¢ botanix pharmaceuticals ltd

Ann: Botanix presents at European Dermatology Conference, page-6

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 3,544 Posts.
    lightbulb Created with Sketch. 318
    As we know or could be enlightened, this 4 to 12 week timeframe is per person.

    So far we could have a 100per cent success rate. It also could be the placebo. Could it be that permetrex itself is such a winner being able to be absorbed into the epidermis better than the active cbd and permetrex combined. I shouldn't think so.

    Phase two will take us into the middle of next year when hundreds of results will be assessed. If we replicate or better phase 1b we should be very happy. Strategically Matt went the longer way with FDA involvement and not the inexpensive five hundred million dollar worth proactive way.

    This is the type of number that potentially exists for long term holders.

    This is only for our acne strategy and not one cent of value attributed for our atopic dermatitis product. Provided the placebo doesnt make our cbd look silly in phase 2.

    There are companies in the states raising a lot of money on nasdaq to fund phase 3 trials . At that time I personally see huge opportunities for us getting involved with folks in the know. They may even come from the PlaceBo derek came from. Or Mr BoJangles. But not BeauBridges.
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
34.0¢
Change
-0.015(4.23%)
Mkt cap ! $707.4M
Open High Low Value Volume
36.0¢ 36.0¢ 34.0¢ $686.4K 1.961M

Buyers (Bids)

No. Vol. Price($)
18 512480 34.0¢
 

Sellers (Offers)

Price($) Vol. No.
34.5¢ 188882 8
View Market Depth
Last trade - 15.00pm 27/11/2024 (20 minute delay) ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.